A Follow-Up, Open-Label, Research Evaluation of Sustained Treatment With Aficamten (CK-3773274) in Hypertrophic Cardiomyopathy (HCM)
A Follow-Up, Open-Label, Research Evaluation of Sustained Treatment With Aficamten (CK-3773274) in Hypertrophic Cardiomyopathy (HCM)
The purpose of this study is to collect long-term safety and tolerability data for aficamten.
Inclusion Criteria:
Exclusion Criteria:
Has received treatment with mavacamten: (a) within 56 days prior to dosing and (b) has not received approval for participation from the Medical Monitor.
Has participated in another investigational device or drug study or received an investigational device or drug < 1 month (or 5 half-lives for drugs, whichever is longer) prior to screening. Other investigational procedures while participating in this study are not permitted.
Since completion of a previous trial of aficamten has:
Had a confirmed LVEF < 40% with an associated dose interruption during participation in a prior study with aficamten
History of implantable ICD placement within 30 days prior to screening.
Ann Arbor, Michigan 48109, United States
New York, New York 10032, United States
Philadelphia, Pennsylvania 19104, United States
Charlottesville, Virginia 22908, United States
Québec, Quebec G1V 4G5, Canada
Nantes, 44093, France
Goettigen, 37075, Germany
Würzburg, 97078, Germany
Pisa, 56124, Italy
Roma, 00189, Italy
Warsaw, 04-628, Poland
Birmingham, B15 2GW, United Kingdom